1. Cue Biopharma announced a public offering of 35.7 million shares. 2. The offering price is set at $0.28 per share. 3. Gross proceeds are expected to be around $10 million. 4. Each warrant has an exercise price of $0.30 and expires in five years. 5. The offering aims to raise funds amid ongoing financial challenges.
FAQ
Why Bearish?
The public offering may dilute existing shares and signals financial strain.
How important is it?
The offering reflects financial needs; impacting investor confidence and stock value.
Why Short Term?
Expect immediate market reactions due to potential dilution and financing concerns.
Cue Biopharma Announces Pricing of $10 Million Public Offering
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has priced an underwritten public offering aimed at raising approximately $10 million.
Details of the Public Offering
Cue Biopharma is set to offer a total of **35,714,286 shares** of its common stock, alongside pre-funded warrants for purchasing additional shares, plus common stock warrants. These securities will be sold at a public offering price of **$0.28** each, or **$0.279** for the pre-funded warrants. The offering is expected to close around **December 22, 2025**, contingent upon customary closing conditions.
- Total shares offered: **35,714,286**
- Common stock warrants to purchase **17,857,143** shares
- Gross proceeds expected: approximately **$10 million**
- Exercise price for warrants: **$0.30** per share
- Warrants are exercisable immediately and will expire in five years
Underwriting and Registration
H.C. Wainwright & Co. serves as the sole book-running manager for the offering, while Newbridge Securities Corporation acts as co-manager.
The shares are being offered under an effective shelf registration statement on Form S-3 (File No. 333-271786) that was filed with the SEC on **May 9, 2023** and declared effective on **May 26, 2023**.
A preliminary prospectus supplement outlining the terms of the offering has been filed with the SEC and is available at www.sec.gov. Interested parties can obtain a final prospectus supplement once filed.
About Cue Biopharma
Cue Biopharma specializes in developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells. This innovative approach aims to harness the body’s intrinsic immune system for treating autoimmune diseases without the adverse effects typical of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, Cue Biopharma is led by a team with extensive experience in immunology and protein engineering.
Forward-Looking Statements
This release may include forward-looking statements per the Private Securities Litigation Reform Act of 1995. These statements encompass various risks and uncertainties, including the successful closing of the public offering and the company’s ability to secure additional financing.
Actual results may differ materially from these expectations due to various factors, including ongoing financial assessments and operational capabilities. The company urges stakeholders not to place undue reliance on these projections.